Literature DB >> 12508246

Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia.

Andreas Reiter1, Susanne Saussele, David Grimwade, Joseph L Wiemels, Mark R Segal, Marina Lafage-Pochitaloff, Christoph Walz, Andreas Weisser, Andreas Hochhaus, Andreas Willer, Anja Reichert, Thomas Büchner, Eva Lengfelder, Rüdiger Hehlmann, Nicholas C P Cross.   

Abstract

The genomic breakpoints in the t(15;17)(q22;q21), associated with acute promyelocytic leukemia (APL), are known to occur within three different PML breakpoint cluster regions (bcr) on chromosome 15 and within RARA intron 2 on chromosome 17; however, the precise mechanism by which this translocation arises is unclear. To clarify this mechanism, we (i). assembled the sequence of RARA intron 2, (ii). amplified and sequenced the genomic PML-RARA junction sequences from 37 APL patients, and (iii). amplified and sequenced the reverse RARA-PML genomic fusion in 29 of these cases. Three significant breakpoint microclusters within RARA intron 2 were identified, suggesting that sequence-associated or structural factors play a role in the formation of the t(15;17). There was no evidence that the location of a breakpoint in PML had any relationship to the location of the corresponding breakpoint in RARA. Although some sequence motifs previously implicated in illegitimate recombinations were found in the microcluster regions, these associations were not significant. Comparison of forward and reverse genomic junctions revealed microhomologies, deletions, and/or duplications of either gene in all but one case, in which a complex rearrangement with inversion of the PML-derived sequence was found. These findings are consistent with the hypothesis that the t(15;17) occurs by nonhomologous recombination of DNA after processing of the double-strand breaks by a dysfunctional DNA damage-repair mechanism. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12508246     DOI: 10.1002/gcc.10154

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  13 in total

1.  Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia.

Authors:  Ashley N Mays; Neil Osheroff; Yuanyuan Xiao; Joseph L Wiemels; Carolyn A Felix; Jo Ann W Byl; Kandeepan Saravanamuttu; Andrew Peniket; Robert Corser; Cherry Chang; Christine Hoyle; Anne N Parker; Syed K Hasan; Francesco Lo-Coco; Ellen Solomon; David Grimwade
Journal:  Blood       Date:  2009-11-02       Impact factor: 22.113

2.  Identification of chromosomal translocation hotspots via scan statistics.

Authors:  Israel T Silva; Rafael A Rosales; Adriano J Holanda; Michel C Nussenzweig; Mila Jankovic
Journal:  Bioinformatics       Date:  2014-05-23       Impact factor: 6.937

Review 3.  Topoisomerases as anticancer targets.

Authors:  Justine L Delgado; Chao-Ming Hsieh; Nei-Li Chan; Hiroshi Hiasa
Journal:  Biochem J       Date:  2018-01-23       Impact factor: 3.857

4.  Rara haploinsufficiency modestly influences the phenotype of acute promyelocytic leukemia in mice.

Authors:  John S Welch; Jeffery M Klco; Nobish Varghese; Rakesh Nagarajan; Timothy J Ley
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

5.  Characteristics features and factors influencing early death in Acute promyelocytic leukemia; Experience from United Arab Emirates (UAE).

Authors:  Inaam Bashir Hassan; Mariam R Al Zaabi; Arif Alam; Mohammed Jawad Hashim; Martin S Tallman; Jorgen Kristensen
Journal:  Int J Hematol       Date:  2017-03-14       Impact factor: 2.490

6.  A model of oncogenic rearrangements: differences between chromosomal translocation mechanisms and simple double-strand break repair.

Authors:  David M Weinstock; Beth Elliott; Maria Jasin
Journal:  Blood       Date:  2005-09-29       Impact factor: 22.113

7.  Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.

Authors:  John S Welch; Peter Westervelt; Li Ding; David E Larson; Jeffery M Klco; Shashikant Kulkarni; John Wallis; Ken Chen; Jacqueline E Payton; Robert S Fulton; Joelle Veizer; Heather Schmidt; Tammi L Vickery; Sharon Heath; Mark A Watson; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Timothy J Ley; Richard K Wilson
Journal:  JAMA       Date:  2011-04-20       Impact factor: 56.272

8.  Breaking down RET breakpoints in lung adenocarcinoma.

Authors:  Hideo Watanabe; Angela N Brooks; Matthew Meyerson
Journal:  J Thorac Oncol       Date:  2014-05       Impact factor: 15.609

Review 9.  Topoisomerase II and leukemia.

Authors:  Maryjean Pendleton; R Hunter Lindsey; Carolyn A Felix; David Grimwade; Neil Osheroff
Journal:  Ann N Y Acad Sci       Date:  2014-02-03       Impact factor: 5.691

10.  Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.

Authors:  Syed Khizer Hasan; Ashley N Mays; Tiziana Ottone; Antonio Ledda; Giorgio La Nasa; Chiara Cattaneo; Erika Borlenghi; Lorella Melillo; Enrico Montefusco; José Cervera; Christopher Stephen; Gnanam Satchi; Anne Lennard; Marta Libura; Jo Ann W Byl; Neil Osheroff; Sergio Amadori; Carolyn A Felix; Maria Teresa Voso; Wolfgang R Sperr; Jordi Esteve; Miguel A Sanz; David Grimwade; Francesco Lo-Coco
Journal:  Blood       Date:  2008-07-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.